Generic drug
Vigabatrin price, strengths & recalls
Vigabatrin has no weekly pharmacy acquisition cost. 14 manufacturers make it. It is in shortage (being discontinued). It has 3 recalls on record, none ongoing. Its official label last changed on June 17, 2026.
Being discontinuedGenericVigabatrin price by strength
What pharmacies pay for each strength and form this week, for the usual package. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay | ||
|---|---|---|---|---|
| 500 mg powder for oral solution | Not priced this week | |||
| 500 mg tablet | Not priced this week | |||
Supply status: shortages & recalls
Shortages
- Vigabatrin, Tablet, 500 mg (NDC 0054-0652-25)The decision to discontinue this drug product was due to a business decision and not due to any reasons of safety or effectiveness.
In a shortage, ask your pharmacist whether another strength, form or maker is in stock, and how much notice they need. What to do in a drug shortage.
Recalls
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
What people paid for Vigabatrin
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use VIGABATRIN FOR ORAL SOLUTION safely and effectively. See full prescribing information for VIGABATRIN FOR ORAL SOLUTION. VIGABATRIN for oral solution Initial U.S. Approval: 2009
WARNING: PERMANENT VISION LOSS
Vigabatrin can cause permanent bilateral concentric visual field constriction, including tunnel vision that can result in disability. In some cases, vigabatrin also can damage the central retina and may decrease visual acuity [see Warnings and Precautions (5.1)].
The onset of vision loss from vigabatrin is unpredictable, and can occur within weeks of starting treatment or sooner, or at any time after starting treatment, even after months or years.
Symptoms of vision loss from vigabatrin are unlikely to be recognized by patients or caregivers before vision loss is severe. Vision loss of milder severity, while often unrecognized by the patient or caregiver, can still adversely affect function.
The risk of vision loss increases with increasing dose and cumulative exposure, but there is no dose or exposure known to be free of risk of vision loss.
Vision assessment is recommended at baseline (no later than 4 weeks after starting vigabatrin), at least every 3 months during therapy, and about 3 to 6 months after the discontinuation of therapy.
Once detected, vision loss due to vigabatrin is not reversible. It is expected that, even with frequent monitoring, some patients will develop severe vision loss.
Consider drug discontinuation, balancing benefit and risk, if vision loss is documented.
Risk of new or worsening vision loss continues as long as vigabatrin is used. It is possible that vision loss can worsen despite discontinuation of vigabatrin.
Because of the risk of vision loss, vigabatrin should be withdrawn from patients with refractory complex partial seizures who fail to show substantial clinical benefit within 3 months of initiation and within 2 to 4 weeks of initiation for patients with infantile spasms, or sooner if treatment failure becomes obvious. Patient response to and continued need for vigabatrin should be periodically reassessed.
Vigabatrin should not be used in patients with, or at high risk of, other types of irreversible vision loss unless the benefits of treatment clearly outweigh the risks.
Vigabatrin should not be used with other drugs associated with serious adverse ophthalmic effects such as retinopathy or glaucoma unless the benefits clearly outweigh the risks.
Use the lowest dosage and shortest exposure to vigabatrin consistent with clinical objectives [see Dosage and Administration (2.1)].
Because of the risk of permanent vision loss, vigabatrin is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Vigabatrin REMS Program [see Warnings and Precautions (5.2)]. Further information is available at www.vigabatrinREMS.com or 1-866-244-8175.
WARNING: PERMANENT VISION LOSS
See full prescribing information for complete boxed warning.
Vigabatrin can cause permanent bilateral concentric visual field constriction, including tunnel vision that can result in disability. In some cases, vigabatrin may also decrease visual acuity (5.1).
Risk increases with increasing dose and cumulative exposure, but there is no dose or exposure to vigabatrin known to be free of risk of vision loss (5.1).
Risk of new and worsening vision loss continues as long as vigabatrin is used, and possibly after discontinuing vigabatrin (5.1).
Baseline and periodic vision assessment is recommended for patients on vigabatrin. However, this assessment cannot always prevent vision damage (5.1).
Vigabatrin is available only through a restricted program called the Vigabatrin REMS Program (5.2).
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Generic makers
- 16 approved generic applications on the market
Vigabatrin questions
Is vigabatrin in shortage?
Yes. 1 product is listed as in shortage or being discontinued (being discontinued). See which ones.
Has vigabatrin been recalled?
3 recalls on record, none ongoing. Recalls name specific lots - check yours.
When did the vigabatrin label last change?
The official label was last updated on June 17, 2026 (version 2). See what changed.
Talk about vigabatrin
No comments yet. Questions, tips, what worked for you - start the conversation.